Addressing Transgender Erasure in HIV Clinical Trials: The Scorecard for Transgender and Gender-Diverse Inclusion.
We sought to offer a structured framework for evaluating transgender and gender-diverse (TGD) inclusion in HIV clinical trials, with actionable criteria for trial design and conduct, and to quantify and characterize TGD inclusion in pivotal HIV studies as supporting evidence of the need for this fra...
| Publicado en: | American Journal of Public Health Vol. 115; no. 10; pp. 1621 - 1631 |
|---|---|
| Autores principales: | , |
| Formato: | Artículo |
| Publicado: |
American Public Health Association
Oct2025
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ssf&AN=187865336&site=ehost-live header: @attributes: shortDbName: ssf uiTerm: 187865336 longDbName: Social Sciences Full Text (H.W. Wilson) uiTag: AN controlInfo: bkinfo: jinfo: jid: 00900036 APH jtl: American Journal of Public Health issn: 00900036 maglogo: N pubinfo: dt: Oct2025 vid: 115 iid: 10 pid: 44 pub: American Public Health Association artinfo: ui: 187865336 10.2105/AJPH.2025.308134 ppf: 1621 ppct: 10 formats: tig: atl: Addressing Transgender Erasure in HIV Clinical Trials: The Scorecard for Transgender and Gender-Diverse Inclusion. aug: au: Minalga, Brian Feuer, Cindra affil: Office of HIV/AIDS Network Coordination, Fred Hutchinson Cancer Center, Seattle, WA. AVAC, New York, NY. su: Health services accessibility Gender-nonconforming people Trans men Self-evaluation Gender identity Human research subjects Clinical trials Gender-neutral language Trans women HIV prevention Patient selection Diversity & inclusion policies Research funding Gender affirming care Descriptive statistics Experimental design Eligibility (Social aspects) Hormone therapy sug: subj: Health services accessibility Gender-nonconforming people Trans men Self-evaluation Gender identity Human research subjects Clinical trials Gender-neutral language Trans women Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology) HIV prevention Patient selection Diversity & inclusion policies Research funding Gender affirming care Descriptive statistics Experimental design Eligibility (Social aspects) Hormone therapy ab: We sought to offer a structured framework for evaluating transgender and gender-diverse (TGD) inclusion in HIV clinical trials, with actionable criteria for trial design and conduct, and to quantify and characterize TGD inclusion in pivotal HIV studies as supporting evidence of the need for this framework. We devised a tool (scorecard) consisting of 14 scoreable indicators for TGD-responsive HIV research with input from global TGD communities. We tested the scorecard in a cross-sectional review of 41 randomized controlled HIV biomedical efficacy trials to measure TGD responsiveness. Studies were selected to represent the spectrum of groundbreaking HIV therapeutic and prevention studies enrolling participants in countries around the world from 1991 to 2023. We found that TGD individuals represent a reported 2532 (1.4%) of 178 893 participants in the selected HIV clinical trials. Scorecard indicators reveal a dearth of HIV research responsive to the needs of TGD communities. The lack of TGD representation in HIV clinical trials indicates a historical erasure of TGD communities with potential public health consequences. The scorecard might guide future HIV research to be more responsive to the needs of TGD people. pubtype: Academic Journal doctype: Article src: R language: English refInfo: copyright: @attributes: flag: N holdings: @attributes: islocal: N |
|---|